BioCentury
ARTICLE | Clinical News

ANG1005: Additional Phase II data

October 28, 2013 7:00 AM UTC

Angiochem said it will continue to develop ANG1005 based on data from 80 patients with brain metastases arising from metastatic breast cancer in the open-label, North American Phase II GRABM-B trial showing that the compound produced 14 partial responses and 35 cases of stable disease. In HER2-positive patients (n=36), ANG1005 produced 9 partial responses and 18 cases of stable disease. At the 550 mg/m 2 dose, ANG1005 led to a 3-month PFS rate of 71%, median PFS of 128 days and a 6-month OS rate of 82% in HER2-positive patients. In HER2-negative patients (n=44), ANG1005 produced 5 partial responses and 17 cases of stable disease. At the 550 mg/m 2 dose, ANG1005 led to a 3-month PFS rate of 35%, median PFS of 84 days and a 6-month OS rate of 60% in HER2-negative patients.

Patients with HER2-negative breast cancer received ANG1005 alone, while patients with HER2-positive breast cancer received ANG1005 plus Herceptin trastuzumab. The initial starting dose of ANG1005 was 650 mg/m 2 (n=13), but was reduced to 550 mg/m 2 (n=67) due to poor tolerance. Data were presented at the Molecular Targets and Cancer Therapeutics meeting in Boston. Next quarter, Angiochem plans to start a Phase II trial with ANG1005 in HER2-postive breast cancer patients with brain metastases. ANG1005 is also in Phase II testing for recurrent high-grade glioma. ...